This retrospective study, published in the Journal of Cardiothoracic Surgery, explores how a simple preoperative blood metric—the Systemic Inflammation Index (SII)—can predict which patients will require prolonged mechanical ventilation (PMV) after heart surgery. By analyzing over 1,100 cases, researchers found that higher SII levels are not only linked to immediate respiratory challenges but also serve as a red flag for lower survival rates three years down the line.
TL;DR
Researchers identified the Systemic Inflammation Index (SII) as a powerful, low-cost preoperative predictor for prolonged mechanical ventilation (>24 hours) following cardiac surgery. Every 100-unit increase in SII correlates with a 7% higher risk of ventilation dependency, and elevated SII is significantly associated with poorer mid-term survival.
What Problem Does This Paper Address?
Recovering from cardiac surgery involving cardiopulmonary bypass (CPB) is a high-stakes process. One of the most common and costly complications is prolonged mechanical ventilation (PMV). Patients who cannot be "weaned" from the ventilator within 24 hours face higher risks of pneumonia, longer ICU stays, and increased mortality.
While risk models for PMV exist, they are often complex or "cumbersome" to use in a fast-paced clinical setting. There is a critical need for a simple, accessible biomarker that can be calculated from routine blood tests before a patient even enters the operating room. This would allow clinicians to identify high-risk individuals and tailor their perioperative care accordingly.
Methods
The authors conducted a retrospective observational study at Nanjing First Hospital, analyzing data from adult patients who underwent cardiac surgery (CABG, valve, or aortic surgery) between January and December 2020.
The core of the study is the Systemic Inflammation Index (SII), calculated using a simple formula: $$\text{SII} = \frac{\text{Neutrophil count} \times \text{Platelet count}}{\text{Lymphocyte count}}$$
By combining these three cell types, the index captures a snapshot of a patient's inflammatory state (neutrophils), immune status (lymphocytes), and coagulation potential (platelets). The researchers used multivariate logistic regression to isolate SII's impact from other variables like age and pre-existing lung disease. They also employed Restricted Cubic Splines (RCS) to visualize the "dose-response" relationship between SII levels and PMV risk.
Datasets
The study utilized a clinical dataset of 1,128 patients (filtered from an initial 1,374 after excluding emergencies, heart transplants, and patients under 18).
- Location: Nanjing First Hospital, China.
- Timeframe: Full year of 2020.
- Follow-up: Median period of 3 years to assess mid-term mortality.
Key Insights and Ideas
- The "Triple Threat" Marker: Unlike looking at white blood cell counts alone, SII integrates three distinct physiological pathways. This makes it a more holistic indicator of how a patient’s body might react to the massive inflammatory "storm" triggered by cardiopulmonary bypass.
- Linear Risk Progression: The risk of PMV doesn't just jump at a specific threshold; it increases steadily. The study found a 7% increase in PMV risk for every 100-unit increase in SII.
- The 650.44 Threshold: Using the Youden index, the researchers identified 650.44 as the optimal cutoff value. Patients above this mark were significantly more likely to experience PMV and had a lower survival rate over the three-year follow-up period.
- Multifactorial Independence: Even after adjusting for heavy hitters like COPD, age, and the complexity of the surgery (e.g., aortic surgery), SII remained a statistically significant independent predictor.
Key Results
- Predictors of PMV: Independent risk factors identified included age (OR 1.06), female gender (OR 1.92), chronic lung disease (OR 3.48), and preoperative SII (OR 1.00 per unit, or 1.07 per 100 units).
- Survival Impact: Patients with PMV had a much higher mid-term mortality rate (Hazard Ratio: 4.58).
- SII and Survival: High preoperative SII (>650.44) was associated with a lower survival rate (Hazard Ratio: 1.89) over three years.
- Hospital Stay: Higher SII levels were directly correlated with longer total hospitalizations.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Center Design: The data comes from one hospital, which may introduce selection bias.
- Retrospective Nature: The study looks backward at existing data; a prospective, randomized trial would be needed to prove that intervening based on SII actually improves outcomes.
- Comparison with Other Markers: While SII performed well, the study did not exhaustively compare it against other emerging markers like the Neutrophil-to-Lymphocyte Ratio (NLR) or Platelet-to-Lymphocyte Ratio (PLR).
Future research should focus on multi-center validation and exploring whether preoperative anti-inflammatory treatments for patients with high SII could successfully reduce the incidence of PMV.
Summary updated